arrow
R

Rahul Banerjee

Fred Hutchinson Cancer Center
H指数:28
被引数:2,526

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early treatment failure after ciltacabtagene autoleucel in multiple myeloma with high-risk features: implications for risk-informed care

具有高危特征的多发性骨髓瘤在应用cilta-cabtagene autoleucel治疗后早期失败:对风险知情护理的启示

2026-10-220
OAAI
Correction: BRIDGE−2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians

更正:BRIDGE−2M:优化多发性骨髓瘤患者CAR-T治疗前桥接治疗:美国医师修改的双盲德尔菲专家组

2026-09-280
OAAI
Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study
2026-08-310
OAAI
BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians

BRIDGE-2M:优化多发性骨髓瘤CAR-T治疗前桥接治疗:美国医师改良双盲德尔菲专家组的评估

2026-08-190
OAAI
Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium
2026-07-270
OA
Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia

BCMA-和GPRC5D-靶向双特异性抗体在浆细胞白血病中的真实世界疗效

2026-07-060
OA
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study

西达基奥仑赛注射液(cilta-cabtagene autoleucel)治疗复发/难治性多发性骨髓瘤的安全性和有效性:一项CIBMTR研究

2026-04-140
OAAI
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium

elranatamab治疗多发性骨髓瘤的真实世界结局: 来自美国多发性骨髓瘤免疫治疗联盟的多中心分析

2026-03-270
OAAI
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience

外周髓外和骨旁浆细胞瘤对使用teclistamab治疗的多发性骨髓瘤患者治疗结局的影响:美国骨髓瘤免疫治疗联盟真实世界经验

2025-11-280
OAAI
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response

多发性骨髓瘤患者对特克替玛初始无应答后延迟应答的预测因子

2025-10-110
OAAI
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy

Dhakal, B.; Akhtar, O.S.; Fandrei, D.; Jensen, A.; Banerjee, R.; Pan, D.; Richard, S.; Friend, R.; Rees, M.J.; Costello, P.; 等. 多发性骨髓瘤的序贯靶向治疗:Talquetamab,一种GPRC5D双特异性抗体,作为BCMA CAR-T细胞疗法的桥梁。Blood 2025. [Google Scholar] [CrossRef]

Blood
IF23.1
2025-08-050
PRE